Cargando…

1467. Clinical Significance of Microbiologic Treatment Failure Following Clinical Cure of Pneumonia

BACKGROUND: Microbiologic cure is a frequent outcome in pneumonia trials, but its clinical relevance remains poorly understood. We aimed to evaluate the association between microbiologic failure in pneumonia in the setting of clinical cure and recurrent pneumonia and mortality. METHODS: Retrospectiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Albin, Owen, Henig, Oryan, Patel, Twisha S, Pogue, Jason M, Petty, Lindsay, Valley, Thomas, Mills, John P, Kaye, Keith
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252932/
http://dx.doi.org/10.1093/ofid/ofy210.1297
_version_ 1783373379250683904
author Albin, Owen
Henig, Oryan
Patel, Twisha S
Pogue, Jason M
Petty, Lindsay
Valley, Thomas
Mills, John P
Kaye, Keith
author_facet Albin, Owen
Henig, Oryan
Patel, Twisha S
Pogue, Jason M
Petty, Lindsay
Valley, Thomas
Mills, John P
Kaye, Keith
author_sort Albin, Owen
collection PubMed
description BACKGROUND: Microbiologic cure is a frequent outcome in pneumonia trials, but its clinical relevance remains poorly understood. We aimed to evaluate the association between microbiologic failure in pneumonia in the setting of clinical cure and recurrent pneumonia and mortality. METHODS: Retrospective, single-center cohort study of adult patients hospitalized between January 1, 2008 and January 1, 2017. Patients with index pneumonia (defined as a positive respiratory culture and continuous receipt of ≥5 days of antibiotics) who demonstrated clinical cure (defined as cessation of all antibiotics for ≥48 hours and survival for 7 days following antibiotic completion) were included. All included patients had to have follow-up respiratory cultures obtained between 3 days before and 7 days after completion of antibiotic therapy. Patients with persistence of the inciting pathogen were classified as microbiologic failure and all others as microbiologic cure. Primary outcomes were 30-day mortality and a 30-day composite of mortality and/or recurrent pneumonia. RESULTS: Of 376 included patients, 61% had microbiologic cure compared with 39% with microbiologic failure. Mean age was 55.4 years, 62% of patients were male and 79% White. Mean antibiotic duration was 14.8 days. Sixty-one percent of patients were mechanically ventilated at the time of index pneumonia. The most common pathogens were Enterobacteriaceae (35%), Staphylococcus aureus (31%) and Pseudomonas aeruginosa (22%). In the microbiologic failure group, the primary composite outcome occurred in 18.9% of patients compared with 11.8% in the microbiologic cure group (OR 1.73, 95% CI 0.98–3.09) (Figure 1). All-cause 30-day mortality was greater in patients with microbiologic failure (16.2%) than microbiologic cure (8.3%) (OR 2.13, 95% CI 1.12–4.04). These associations were particularly strong among nonventilated patients (Figure 2). Rates of recurrent pneumonia were similar between groups. CONCLUSION: Patients with clinical cure but microbiologic failure were more than twofold more likely to die 30 days after their index pneumonia than those with microbiologic cure. Patients with microbiologic failure who were not mechanically ventilated at the time of index pneumonia had a greater than fourfold increased mortality risk. [Image: see text] [Image: see text] DISCLOSURES: K. Kaye, Zavante Therapeutics, Inc.: Scientific Advisor, Consulting fee
format Online
Article
Text
id pubmed-6252932
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-62529322018-11-28 1467. Clinical Significance of Microbiologic Treatment Failure Following Clinical Cure of Pneumonia Albin, Owen Henig, Oryan Patel, Twisha S Pogue, Jason M Petty, Lindsay Valley, Thomas Mills, John P Kaye, Keith Open Forum Infect Dis Abstracts BACKGROUND: Microbiologic cure is a frequent outcome in pneumonia trials, but its clinical relevance remains poorly understood. We aimed to evaluate the association between microbiologic failure in pneumonia in the setting of clinical cure and recurrent pneumonia and mortality. METHODS: Retrospective, single-center cohort study of adult patients hospitalized between January 1, 2008 and January 1, 2017. Patients with index pneumonia (defined as a positive respiratory culture and continuous receipt of ≥5 days of antibiotics) who demonstrated clinical cure (defined as cessation of all antibiotics for ≥48 hours and survival for 7 days following antibiotic completion) were included. All included patients had to have follow-up respiratory cultures obtained between 3 days before and 7 days after completion of antibiotic therapy. Patients with persistence of the inciting pathogen were classified as microbiologic failure and all others as microbiologic cure. Primary outcomes were 30-day mortality and a 30-day composite of mortality and/or recurrent pneumonia. RESULTS: Of 376 included patients, 61% had microbiologic cure compared with 39% with microbiologic failure. Mean age was 55.4 years, 62% of patients were male and 79% White. Mean antibiotic duration was 14.8 days. Sixty-one percent of patients were mechanically ventilated at the time of index pneumonia. The most common pathogens were Enterobacteriaceae (35%), Staphylococcus aureus (31%) and Pseudomonas aeruginosa (22%). In the microbiologic failure group, the primary composite outcome occurred in 18.9% of patients compared with 11.8% in the microbiologic cure group (OR 1.73, 95% CI 0.98–3.09) (Figure 1). All-cause 30-day mortality was greater in patients with microbiologic failure (16.2%) than microbiologic cure (8.3%) (OR 2.13, 95% CI 1.12–4.04). These associations were particularly strong among nonventilated patients (Figure 2). Rates of recurrent pneumonia were similar between groups. CONCLUSION: Patients with clinical cure but microbiologic failure were more than twofold more likely to die 30 days after their index pneumonia than those with microbiologic cure. Patients with microbiologic failure who were not mechanically ventilated at the time of index pneumonia had a greater than fourfold increased mortality risk. [Image: see text] [Image: see text] DISCLOSURES: K. Kaye, Zavante Therapeutics, Inc.: Scientific Advisor, Consulting fee Oxford University Press 2018-11-26 /pmc/articles/PMC6252932/ http://dx.doi.org/10.1093/ofid/ofy210.1297 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Albin, Owen
Henig, Oryan
Patel, Twisha S
Pogue, Jason M
Petty, Lindsay
Valley, Thomas
Mills, John P
Kaye, Keith
1467. Clinical Significance of Microbiologic Treatment Failure Following Clinical Cure of Pneumonia
title 1467. Clinical Significance of Microbiologic Treatment Failure Following Clinical Cure of Pneumonia
title_full 1467. Clinical Significance of Microbiologic Treatment Failure Following Clinical Cure of Pneumonia
title_fullStr 1467. Clinical Significance of Microbiologic Treatment Failure Following Clinical Cure of Pneumonia
title_full_unstemmed 1467. Clinical Significance of Microbiologic Treatment Failure Following Clinical Cure of Pneumonia
title_short 1467. Clinical Significance of Microbiologic Treatment Failure Following Clinical Cure of Pneumonia
title_sort 1467. clinical significance of microbiologic treatment failure following clinical cure of pneumonia
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252932/
http://dx.doi.org/10.1093/ofid/ofy210.1297
work_keys_str_mv AT albinowen 1467clinicalsignificanceofmicrobiologictreatmentfailurefollowingclinicalcureofpneumonia
AT henigoryan 1467clinicalsignificanceofmicrobiologictreatmentfailurefollowingclinicalcureofpneumonia
AT pateltwishas 1467clinicalsignificanceofmicrobiologictreatmentfailurefollowingclinicalcureofpneumonia
AT poguejasonm 1467clinicalsignificanceofmicrobiologictreatmentfailurefollowingclinicalcureofpneumonia
AT pettylindsay 1467clinicalsignificanceofmicrobiologictreatmentfailurefollowingclinicalcureofpneumonia
AT valleythomas 1467clinicalsignificanceofmicrobiologictreatmentfailurefollowingclinicalcureofpneumonia
AT millsjohnp 1467clinicalsignificanceofmicrobiologictreatmentfailurefollowingclinicalcureofpneumonia
AT kayekeith 1467clinicalsignificanceofmicrobiologictreatmentfailurefollowingclinicalcureofpneumonia